Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 1/5 criteria met.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 389.36%
Price change 2019 → 2020: -3.78%
Price change 2020 → 2021: 21.81%
Price change 2021 → 2022: -66.61%
Price change 2022 → 2023: -15.46%
Price change 2023 → 2024: 30.29%
Price change 2024 → 2025: 0.88%
Price change 2025 → 2026: -47.83%
Price change 2026 (year to date): -48.28%
Financial growth
Revenue CAGR (8 years): 1.41%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 0.29
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -6.94
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 42.31% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="STXS" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Stereotaxis, Inc. | – | 0.29 | −3.4 % | 🔒 |
| Organogenesis Holdings Inc. | 27.1 | 0.31 | – | – |
| Coherus Oncology, Inc. | – | 0.66 | +26.9 % | – |
| OrganiGram Holdings Inc. | 2.1 | 0.03 | – | – |
| Onward Medical N.V. | – | 0.25 | +34.5 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Stereotaxis, Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 26.6 m | -6.6 m | -25.0 % | n/a |
| 2021 | 35.0 m | -10.7 m | -30.6 % | +31.5 % |
| 2022 | 28.1 m | -18.3 m | -65.0 % | -19.6 % |
| 2023 | 26.8 m | -20.7 m | -77.4 % | -4.9 % |
| 2024 | 26.9 m | -24.0 m | -89.3 % | +0.5 % |
| 2025 | 32.4 m | -21.6 m | -66.8 % | +20.3 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Stereotaxis, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 38.7 m | 28.4 m | 19.8 m | 12.2 m | 13.4 m |
| Total Debt | 6.1 m | 5.9 m | 5.5 m | 6.0 m | 5.4 m |
| Net Debt | -32.6 m | -2.7 m | -14.3 m | -6.2 m | -8.0 m |
| Equity | 39.4 m | 31.9 m | 21.9 m | 11.4 m | 18.7 m |
| Total assets | 61.0 m | 53.4 m | 41.9 m | 46.7 m | 52.3 m |
| Operating cash flow | -2.9 m | -8.4 m | -9.1 m | -8.5 m | -13.7 m |
| Investments (capex) | 1.4 m | 2.4 m | 366,000 | 34,000 | 93,000 |
| Free cash-flow | -4.3 m | -10.8 m | -9.5 m | -8.5 m | -13.8 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 18/11/2026.
Analyst consensus and forecasts
What the financial analysts covering Stereotaxis, Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Track record against expectations: reported EPS above consensus 4 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
Stereotaxis, Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 10/11/2026 | -0.07 | -0.05 | n/a |
| 11/08/2026 | -0.05 | -0.05 | n/a |
| 12/05/2026 | -0.03 | -0.04 | n/a |
| 09/03/2026 | -0.06 | -0.06 | n/a |
| 11/11/2025 | -0.03 | -0.06 | n/a |
| 07/08/2025 | -0.05 | -0.07 | n/a |
Stock splits
| Date | Operation |
|---|---|
| 04/11/2013 | split: 137 shares for 125 |
| 11/07/2012 | reverse split: 1 share for 10 |
Factual data: ex-dividend history and earnings calendar, as of 18/11/2026. A past dividend does not guarantee the next one.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Stereotaxis, Inc.
What is the Stereotaxis, Inc. share price?
Latest recorded price: 0.843 USD on 13/11/2026, for a market cap of 84.5 m USD.
What is the revenue of Stereotaxis, Inc.?
32.4 m USD for fiscal year 2025, with net income of -21.6 m USD (net margin -66.8 %).
What do analysts say about Stereotaxis, Inc.?
Out of 12 analysts: 12 buy or strong buy, 0 hold, 0 sell or strong sell.
Is Stereotaxis, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US85916J4094).
How many employees does Stereotaxis, Inc. have?
139 full-time employees according to the latest published profile.
Who runs Stereotaxis, Inc.?
David Leo Fischel C.A.I.A., is the company's chief executive.